Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study

scientific article

Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3350/CMH.2015.21.4.379
P932PMC publication ID4712166
P698PubMed publication ID26770927
P5875ResearchGate publication ID290511173

P50authorNayoung KimQ40152658
Sook-Hyang JeongQ88677490
P2093author name stringDong Ho Lee
Jin-Wook Kim
Young Soo Park
Jin-Hyeok Hwang
Jong Ho Lee
Eun Sun Jang
Jaihwan Kim
Cheol Min Shin
Kyeong Sam Ok
Jung Wha Chung
Gi Hyun Kim
P2860cites workPioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisQ24625697
Vitamin E and nonalcoholic fatty liver diseaseQ27693883
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of GastroenterologyQ28267844
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adultsQ29614911
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definitionQ29615691
Molecular mediators of hepatic steatosis and liver injuryQ29616709
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationQ29617157
The natural history of nonalcoholic fatty liver disease: a population-based cohort studyQ29617161
Long-term follow-up of patients with NAFLD and elevated liver enzymesQ29620024
Therapy of NAFLD: antioxidants and cytoprotective agentsQ30439787
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitisQ33563333
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic associationQ34112671
Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes FederationQ34567335
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trialQ35031127
Seoul National University Bundang Hospital's Electronic System for Total CareQ36109910
The molecular basis for oxidative stress-induced insulin resistanceQ36184182
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.Q36952308
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitisQ37177461
Oxidative stress and insulin resistance: the coronary artery risk development in young adults study.Q37235949
The epidemiology of nonalcoholic fatty liver disease: a global perspectiveQ37310275
KASL clinical practice guidelines: management of nonalcoholic fatty liver diseaseQ37488800
Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysisQ37841383
Features, diagnosis, and treatment of nonalcoholic fatty liver diseaseQ37996848
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupQ39605645
Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.Q42234528
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obeseQ43662697
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndromeQ43875846
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionQ44323346
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeQ44385945
Identification of individuals with insulin resistance using routine clinical measurementsQ45242074
Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis.Q45939192
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trialQ46216843
Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.Q51781353
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDQ61989968
Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver diseaseQ79269614
Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summaryQ80470858
Is vitamin E beneficial in chronic liver disease?Q80696380
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver diseaseQ83706587
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 yearsQ84484058
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectmetabolic syndromeQ657193
metabolic dysfunction–associated steatotic liver diseaseQ1546498
fatty liver diseaseQ6058862
P304page(s)379-386
P577publication date2015-12-24
P1433published inClinical and molecular hepatologyQ26853927
P1476titleEffect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study
P478volume21